Ali Rizvi to Dyslipidemias
This is a "connection" page, showing publications Ali Rizvi has written about Dyslipidemias.
Connection Strength
1.757
-
Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. Expert Rev Cardiovasc Ther. 2022 Jul; 20(7):515-527.
Score: 0.751
-
Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2019 Feb; 12(2):129-143.
Score: 0.591
-
Association of clinical and therapeutic factors with incident dyslipidemia in a cohort of human immunodeficiency virus-infected and non-infected adults: 1994-2011. Metab Syndr Relat Disord. 2013 Dec; 11(6):417-26.
Score: 0.101
-
Non-glycemic effects of pioglitazone and incretin-based therapies. Expert Opin Ther Targets. 2013 Jul; 17(7):739-42.
Score: 0.100
-
Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr Pharm Des. 2013; 19(21):3858-68.
Score: 0.097
-
The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance? Acta Diabetol. 2009 Mar; 46(1):1-11.
Score: 0.073
-
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opin Drug Saf. 2022 Jan; 21(1):9-20.
Score: 0.045